Copyright
©The Author(s) 2019.
World J Gastroenterol. Sep 7, 2019; 25(33): 4985-4998
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4985
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4985
Table 3 Rates of positive detection of hepatitis B virus wild type (YMDD) and rtM204I variant (YIDD) in 410 samples by LNA real-time PCR
Type of detection | No. of samples | Percentage |
Clinical samples | 410 | 100% |
Identified | 403 | 98.3% |
YIDD | 17 | 4.1% |
YIDD exclusively | 9 | 2.2% |
YIDD + YMDD | 3 | 0.7% |
YIDD + YMDD + YIDD with ATA codon1 | 1 | 0.2% |
YIDD + YMDD | 1 | 0.5% |
YIDD + YMDD | 3 | 0.7% |
YMDD | 394 | 96.3% |
YMDD exclusively | 385 | 93.9% |
YMDD + unknown variant | 1 | 0.2% |
Unidentified | 7 | 1.7% |
Non-target Tm | 2 | 0.5% |
HEX 50.4 °C; YVDD1 | 1 | 0.2% |
HEX 57.9 °C; YMDD with Y of TAC codon1 | 1 | 0.2% |
No positive signal | 5 | 1.2% |
- Citation: Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998
- URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i33.4985